For more than 80 years, men have been told that testosterone helps prostate cancer grow. But a very different picture has emerged over the past two decades.

Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Most prostate cancers become castration-resistant in about two to ...

Targeting the androgen receptor by depriving testosterone with gonadotropin-releasing hormone agonists or antagonists, or surgical castration, has been the backbone of metastatic prostate cancer ...

Behavioral interventions, such as cognitive behavioral therapy (CBT) and physical activity, can help mitigate adverse effects of androgen-deprivation therapy (ADT), including fatigue, depressive ...

Evaluating survival post-7 mo PSA response, stratified by response, disease extent, and intermittent vs. continuous ADT in mHSPC: The S9346 trial. No AR alteration (n=326) AR alteration present (n=225 ...

If you have prostate cancer, your health care provider may have told you about a medicine called Nubeqa (darolutamide). The FDA approved Nubeqa in 2019. It is commonly used to treat prostate cancer ...

New research sheds light on the significance of the glucocorticoid receptor in drug-resistant prostate cancer, showing that the development of drug resistance could be prevented by limiting the ...

Joe Biden’s recent diagnosis of "aggressive" prostate cancer has sparked concerns about how far the disease has advanced. The former president’s prostate cancer has been characterized by a Gleason ...